The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Goldman Sachs brings back coverage on Medtronic with a Neutral call
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 9, 2:08 PM EDT

Goldman Sachs brings back coverage on Medtronic with a Neutral call

The bank reinstated research coverage on Medtronic plc, assigning a Neutral rating and setting a $84 price target, according to market reporting.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Goldman Sachs has reinstated analyst coverage of Medtronic plc (NYSE:MDT), stepping back into the stock’s research picture with a Neutral rating and a $84 price target, according to a recent market report published by Yahoo Finance.

The move, dated May 21 in the reporting, marks a fresh evaluation of Medtronic’s outlook after a period in which the company was not under that specific firm’s published coverage, at least as reflected in the market data cited by the article.

In the same update, Goldman’s stance was framed as mixed. A Neutral rating generally indicates that the analyst does not see a clear near-term edge toward upside or downside relative to other opportunities, and the price target indicates the level Goldman believes the shares could reach by a specified horizon. In this case, the reported target is $84, tied to Medtronic’s trading performance at the time of the note.

Goldman did not, in the excerpted market report, provide detailed fundamentals such as changes to Medtronic’s revenue expectations, margin outlook, or product pipeline assumptions. The report likewise did not lay out specific catalysts or risks behind the Neutral rating, leaving investors to look for those details in the original analyst note or subsequent disclosures.

Medtronic is one of the largest medical technology companies, spanning areas such as cardiac rhythm management, structural heart interventions, diabetes care, and surgical solutions. For large medtech firms, analyst coverage changes often reflect shifts in expectations about demand for procedure-linked devices, pricing dynamics, and the timing of new platform launches or regulatory outcomes.

The market update also fits into a broader pattern in healthcare equities, where coverage can be reinstated when banks reassess near-term visibility, competitive positioning, or valuation against peers. For Medtronic specifically, investors typically watch how its installed base of devices and procedure demand translate into growth, and how product mix and cost discipline affect earnings durability.

Still, investors should note what is not provided in the reporting: beyond the rating and the $84 target, the article does not specify the key drivers Goldman cited, the assumptions used to build the target, or whether the bank expects material changes to Medtronic’s guidance. Without those details, the practical takeaway is primarily that Goldman has resumed coverage with an explicitly balanced view rather than a clearly bullish or bearish one.

Why It Matters

  • A reinstatement of coverage can announcement that Goldman is again willing to update its model on Medtronic’s fundamentals, potentially affecting how other investors interpret consensus views.
  • A Neutral rating suggests Goldman sees limited conviction on near-term direction, which can matter for positioning around earnings and product-cycle catalysts.
  • The $84 price target provides a reference point for valuation, even though the reporting does not disclose the specific drivers behind it.
  • Because the rationale is not detailed in the cited market update, investors may need to wait for additional reporting or the underlying note to understand what changed.

Sources

Key Facts

  • Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT), dated May 21, according to market reporting.
  • Goldman assigned a Neutral rating to Medtronic in the reinstated coverage.
  • The reinstated coverage included a $84 price target.
  • The market report summarized the rating and target but did not include granular rationale or model assumptions.

Finance Related

Goldman Sachs brings back coverage on Medtronic with a Neutral call | The Apex Times